Pipeline

Pioneering Treg-Targeted Therapies

Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction:
Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.

Coya 301 (Subcutaneous Administration)
Frontotemporal Dementia
Coya 302* (Biologic Combination)
Neurodegenerative Diseases
Coya 302* (Biologic Combination)

Autoimmune Diseases

Coya 201
Neurodegenerative, Autoimmune, and Metabolic Diseases
Coya 206
Undisclosed Indications

Leveraging COYA 101 data generated in two IIT studies to advance Treg-Derived Exosomes for treatment of Neurodegenerative and Autoimmune Diseases

Coya 101 (Autologous IV Administration)
Amyotrophic Lateral Sclerosis

* Proof-of-Concept clinical data has been generated in an Investigator-Initiated Trial conducted at Houston Methodist Hospital.

Pioneering Treg-Targeted Therapies

Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction: Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.

Coya 301 (Subcutaneous Administration)
Frontotemporal Dementia
Coya 302* (Biologic Combination)
Neurodegenerative Diseases
Coya 302* (Biologic Combination)

Autoimmune Diseases

Coya 201 Platform
Neurodegenerative, Autoimmune, and Metabolic Diseases

Leveraging COYA 101 data generated in two IIT studies to advance Treg-Derived Exosomes for treatment of Neurodegenerative and Autoimmune Diseases

Coya 101 (Autologous IV Administration)
Amyotrophic Lateral Sclerosis

* Proof-of-Concept clinical data has been generated in an Investigator-Initiated Trial conducted at Houston Methodist Hospital.

Pioneering Treg-Targeted Therapies

Our broad pipeline combines three therapeutic modalities targeting Treg dysfunction: Treg modifying biologics, allogeneic Treg-derived exosomes, and autologous Treg cell therapy.

COYA 301

Frontotemporal Dementia

Coya 302*

Neurodegenerative Diseases

Coya 302*

Autoimmune Diseases

Coya 201

Neurodegenerative, Autoimmune, and Metabolic Diseases

Leveraging COYA 101 data generated in two IIT studies to advance Treg-Derived Exosomes for treatment of Neurodegenerative and Autoimmune Diseases

Coya 101

Amyotrophic Lateral Sclerosis

* Proof-of-Concept clinical data has been generated in an Investigator-Initiated Trial conducted at Houston Methodist Hospital.